Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), filed a Form 4 on September 1, 2026, disclosing the exercise of stock options and a same-day sale of 1,452 shares of common stock pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Hansen acquired 1,452 shares of common stock on September 1, 2026, at an exercise price of $1.86 per share via transaction code M.
  • Same-day sale: Hansen disposed of 1,452 shares on September 1, 2026, at $25.47 per share via transaction code S.
  • Post-transaction ownership: Hansen directly beneficially owns 117,227 shares of common stock following the reported transactions.
  • Remaining derivative securities: Hansen holds 60,858 employee stock options (right to buy) with an exercise price of $1.86 and an expiration date of August 28, 2029.
  • 10b5-1 plan: According to the filing, both the option exercise and the sale were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
  • Option vesting history: The filing states the exercised stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019, until fully vested on May 10, 2023.

Nurix Therapeutics CSO Reports Option Exercise and Share Disposal

According to the Form 4 filed with the SEC on September 1, 2026, Gwenn Hansen, serving as Chief Scientific Officer of Nurix Therapeutics, Inc., exercised employee stock options covering 1,452 shares of common stock at an exercise price of $1.86 per share. On the same date, Hansen sold those 1,452 shares at a price of $25.47 per share. The filing indicates both transactions were carried out under a previously established Rule 10b5-1 trading plan.

Prior to the reported transactions, Hansen's direct beneficial ownership stood at 118,679 shares. Following the exercise and sale, the filing reports direct beneficial ownership of 117,227 shares of common stock. In Table II, the filing discloses that Hansen retains 60,858 employee stock options with an exercise price of $1.86, expiring August 28, 2029, with a reported price of $0 for the derivative security in connection with the exercise transaction.

The Form 4 was signed by Daniel Burbach as Attorney-in-Fact for Gwenn Hansen and dated September 1, 2026. The filing further notes that the exercised option vested at a rate of 1/48 of the total shares monthly, beginning June 10, 2019, and became fully vested on May 10, 2023.

What Was Disclosed

The filing discloses a stock option exercise and same-day sale of 1,452 shares by Nurix Therapeutics' Chief Scientific Officer on September 1, 2026, both conducted under a Rule 10b5-1 plan, leaving her with direct beneficial ownership of 117,227 shares.